With patisiran launch in its sights, Alnylam plots a major hiring spree

Alnylam’s first drug approval could come any day now, and in preparation, the company is bulking up—in more ways than one.

The RNAi-focused biotech is going on a hiring spree that will double its roster by 2020, the Boston Business Journal reports. Its staff, which grew from 750 to 800 over the past three months, is set to expand to 1,500 workers by the end of 2020.